Ken Griffin Citadel Advisors
Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$1.16B |
| 2 |
Uber
UBER
|
+$452M |
| 3 |
Analog Devices
ADI
|
+$421M |
| 4 |
Walt Disney
DIS
|
+$376M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$375M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$1.55B |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.08B |
| 3 |
Bristol-Myers Squibb
BMY
|
+$430M |
| 4 |
NVIDIA
NVDA
|
+$368M |
| 5 |
JPMorgan Chase
JPM
|
+$365M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 3.78% |
| 2 | Healthcare | 3.27% |
| 3 | Industrials | 2.02% |
| 4 | Financials | 2.02% |
| 5 | Consumer Discretionary | 1.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
7551
Lifecore Biomedical
LFCR
$179M
| $638K | ﹤0.01% |
+58,795
| New | +$607K |
|
7552
Myriad Genetics
MYGN
$290M
| $638K | ﹤0.01% |
32,258
-5,573
| -15% | -$90K |
|
7553
CALL
Ocular Therapeutix
OCUL
$2.2B
| $638K | ﹤0.01% |
30,800
+5,700
| +23% | +$84.7K |
|
7554
PUT
Prestige Consumer Healthcare
PBH
$2.43B
| $638K | ﹤0.01% |
+18,300
| New | +$650K |
|
7555
T. Rowe Price
TROW
$23.6B
| $638K | ﹤0.01% |
4,213
-180,612
| -98% | -$25.8M |
|
7556
Capital City Bank Group
CCBG
$898M
| $637K | ﹤0.01% |
25,918
-853
| -3% | -$19.6K |
|
7557
ProShares UltraShort Energy
DUG
$18.1M
| $637K | ﹤0.01% |
+1,104
| New | +$922K |
|
7558
PUT
IDEX
IEX
$17.6B
| $637K | ﹤0.01% |
3,200
-4,900
| -60% | -$932K |
|
7559
Quanex
NX
$962M
| $637K | ﹤0.01% |
28,734
-3,203
| -10% | -$65.9K |
|
7560
Old Second Bancorp
OSBC
$1.32B
| $637K | ﹤0.01% |
63,023
-7,993
| -11% | -$75.9K |
|
7561
Cedar Fair
FUN
$1.68B
| $636K | ﹤0.01% |
+16,177
| New | +$538K |
|
7562
Hooker Furnishings Corp
HOFT
$158M
| $636K | ﹤0.01% |
19,726
+667
| +3% | +$20.2K |
|
7563
Virtus Reaves Utilities ETF
UTES
$1.33B
| $636K | ﹤0.01% |
15,823
-19,035
| -55% | -$765K |
|
|
BFX
7564
DELISTED
BowFlex Inc.
BFX
| $636K | ﹤0.01% |
35,060
-101,050
| -74% | -$2.1M |
|
|
OSH
7565
PUT
DELISTED
Oak Street Health, Inc.
OSH
| $636K | ﹤0.01% |
+10,400
| New | +$546K |
|
7566
Virtus Biotech Clinical Trials ETF
BBC
$50.2M
| $635K | ﹤0.01% |
12,801
+2,083
| +19% | +$93.6K |
|
7567
Teucrium Corn Fund
CORN
$171M
| $635K | ﹤0.01% |
40,737
-117,983
| -74% | -$1.65M |
|
|
SILV
7568
CALL
DELISTED
SilverCrest Metals Inc. Common Shares
SILV
| $635K | ﹤0.01% |
56,800
+33,300
| +142% | +$313K |
|
7569
Hess Midstream
HESM
$5.2B
| $634K | ﹤0.01% |
32,377
+4,141
| +15% | +$75K |
|
|
IDLB
7570
DELISTED
Invesco FTSE International Low Beta Equal Weight ETF
IDLB
| $634K | ﹤0.01% |
21,346
-1,199
| -5% | -$33.9K |
|
|
VIVO
7571
CALL
DELISTED
Meridian Bioscience Inc
VIVO
| $634K | ﹤0.01% |
33,900
+13,300
| +65% | +$248K |
|
|
ALE
7572
DELISTED
Allete
ALE
| $633K | ﹤0.01% |
10,220
-19,768
| -66% | -$1.12M |
|
7573
Resideo Technologies
REZI
$3.11B
| $633K | ﹤0.01% |
29,782
-9,858
| -25% | -$158K |
|
7574
Spero Therapeutics
SPRO
$71.6M
| $633K | ﹤0.01% |
32,638
+11,328
| +53% | +$177K |
|
7575
TriNet
TNET
$3.16B
| $633K | ﹤0.01% |
7,858
-1,018
| -11% | -$75.3K |
|
Similar funds
Ken Griffin's Q4 2020 Portfolio in Review
As of Q4 2020, Ken Griffin held 11,975 positions worth $385B, up 9.1% from $353B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Ken Griffin withdrew a net $35.1B in Q4 2020, closing 1,130 positions and reducing 4,218 holdings. Its most notable exit was Immunomedics Inc, an estimated $213M position sold in full.
By sector, the portfolio is most concentrated in Technology at 3.8% of assets, up from 3% a quarter earlier, followed by Healthcare and Industrials.
Against the trend, Ken Griffin opened a new position in S&P Global worth $114M.
- Ken Griffin's largest Q4 2020 buy was S&P Global: 345,785 shares worth $114M.
- Ken Griffin added most to iShares Core S&P 500 ETF in Q4 2020, an estimated $1.16B increase.
- Ken Griffin's biggest Q4 2020 reduction was Amazon, cutting an estimated $1.55B.
- Ken Griffin fully exited Immunomedics Inc in Q4 2020, selling an estimated $213M.
- Ken Griffin's ten largest holdings make up 31% of its $385B portfolio in Q4 2020.
- Ken Griffin opened 1,988 new positions and closed 1,130 in Q4 2020.
- Ken Griffin's portfolio value rose 9.1% quarter-over-quarter to $385B.
Based on Citadel Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.